ArticleJournal of neuro-oncology2012
IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 4 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.Archives of pathology & laboratory medicine · 2022Guideline
- Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.Neurologia medico-chirurgica · 2022Pooled it
- Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2015Guideline
- Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.Journal of neuro-oncology · 2013Pooled it
- Prognostic Value of Conventional Magnetic Resonance Imaging for Adult Patients with Brain Tumors.Clinical neuroradiology · 2015Trial
- Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database.Pediatric blood & cancer · 2014Trial
- State of the Art of IDH Inhibitors: Emerging Questions and Perspectives.Anti-cancer agents in medicinal chemistry · 2026Review
- Differential Effects of Sphingolipids on Cell Death and Antioxidant Defenses in Type 1 and Type 2 Endometrial Cancer Cells.International journal of molecular sciences · 2025Article
- A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.Neuro-oncology · 2024Article
- Current status of precision oncology in adult glioblastoma.Molecular oncology · 2024Review
- The Interplay between Oxidative Stress and Sphingolipid Metabolism in Endometrial Cancer.International journal of molecular sciences · 2024Article
- Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2024Article
- Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.Neuro-oncology practice · 2024Article
- Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Article
- Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing.Journal of neuro-oncology · 2023Article
- Rapid detection of isocitrate dehydrogenase 1 mutation status in glioma based on Crispr-Cas12a.Scientific reports · 2023Article
- Kynureninase Promotes Immunosuppression and Predicts Survival in Glioma Patients: In Silico Data Analyses of the Chinese Glioma Genome Atlas (CGGA) and of the Cancer Genome Atlas (TCGA).Pharmaceuticals (Basel, Switzerland) · 2023Article
- Image-localized biopsy mapping of brain tumor heterogeneity: A single-center study protocol.PloS one · 2023Article
- An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?Frontiers in oncology · 2023Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the prognostic and predictive significance of IDH1 and IDH2 mutations in low-grade astrocytomas (LGA). The presence and consistency of IDH mutations during the progression of LGA to secondary high-grade gliomas (sHGG) were detected. Samples of patients with LGA and sHGG were investigated. The genomic regions around IDH1 codon 132 and IDH2 codon 172 were PCR amplified and directly sequenced. Furthermore, the MGMT promoter status was provided using the methylation-specific PCR. Our population comprised 71 patients with a total of 45 pairs of LGA and their consecutive sHGG. Median follow-up was 9.6 years. IDH mutations were found in 36/45 LGA (80%) and their sHGG without changes in the mutation status. A total of 71 patients with LGA were analyzed according to clinical and molecular tumor-related factors: 56/71 patients (78.8%) had an IDH mutation without significant influence on the progression-free or overall survival (OS), and 22/71 (31%) of the patients received postoperative radiotherapy (RT) after diagnosis of LGA. Patients with early RT but without IDH mutations had the shortest survival. Our study shows that IDH mutation status is stable during the progression course of LGA to sHGG. The presence of IDH mutations fails to demonstrate a significant influence on survival in the multivariate analysis of LGA patients. Early RT appears to be beneficial only LGA patients with IDH-mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.